SML2673
Deferasirox
≥98% (HPLC), iron chelator, powder
别名:
4-[3,5-bis(2-Hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C21H15N3O4
化学文摘社编号:
分子量:
373.36
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
产品名称
Deferasirox, ≥98% (HPLC)
SMILES string
N2(N\C(=C4\C=CC=CC\4=O)\N\C\2=C3\C=CC=CC\3=O)c1ccc(cc1)C(=O)O
InChI
1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,22-23H,(H,27,28)/b19-15-,20-16+
InChI key
FMSOAWSKCWYLBB-VBGLAJCLSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
正在寻找类似产品? 访问 产品对比指南
Application
Deferasirox has been used as an iron chelator to test its effect on clofazimine mediated growth inhibition and rescue in Salmonella typhimurium.
Biochem/physiol Actions
Deferasirox belongs to the N-substituted bis-hydroxyphenyl-triazole family of tridentate iron chelators.
Deferasirox is an orally available iron chelator used clinically for reduction of chronic iron overload in diseases such as β-thalassemia.
Orally available iron chelator
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Acute 1
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Omid Reza Zekavat et al.
Journal of pediatric hematology/oncology, 43(1), e26-e28 (2020-09-15)
This study was performed on patients with transfusion-dependent beta-thalassemia (TDT) to investigate the effect of HFE gene mutations of iron overload in a large group of patients with TDT major and its relationship with heart and liver T2* magnetic resonance
Abbas Rahdar et al.
Life sciences, 270, 119146-119146 (2021-02-06)
Deferasirox (DFX) was formulated into oil-in-water microemulsions in the presence of pluronicto improve its oral bioavailability. The size of the DFX-loadedmicroemulsions system measured by dynamic light scattering (DLS) was about 9 nm. The anti-proliferative and anti-lipid peroxidation effects of DFX and
Nesma Ahmed Safwat et al.
Pediatric research, 89(1), 185-190 (2020-06-17)
The genetic variants of the receptor for advanced glycation end products (RAGE) gene have been associated with vascular disease risk. The objective of this work was to explore the association of three single-nucleotide polymorphisms (SNPs) of RAGE gene (374T/A, 429T/C
Aurelio Maggio et al.
The Lancet. Haematology, 7(6), e469-e478 (2020-05-30)
Transfusion-dependent haemoglobinopathies require lifelong iron chelation therapy with one of the three iron chelators (deferiprone, deferasirox, or deferoxamine). Deferasirox and deferiprone are the only two oral chelators used in adult patients with transfusion-dependent haemoglobinopathies. To our knowledge, there are no
Claudia Bollig et al.
The Cochrane database of systematic reviews, 8, CD007476-CD007476 (2017-08-16)
Thalassaemia is a hereditary anaemia due to ineffective erythropoiesis. In particular, people with thalassaemia major develop secondary iron overload resulting from regular red blood cell transfusions. Iron chelation therapy is needed to prevent long-term complications.Both deferoxamine and deferiprone are effective;
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持